Literature DB >> 21745034

HIV-related neurocognitive impairment--a review.

Simon Rackstraw1.   

Abstract

Neurocognitive impairments following central nervous system opportunistic infections and HIV-associated dementia (HAD) were common clinical features of HIV infection prior to anti-retroviral therapy. As HIV infection has evolved from an invariably fatal disease with a poor prognosis to a condition requiring long-term management, HIV-related neurocognitive disorders have been the subject of increasing research. This review will examine the recent changes in the understanding of the HIV-associated neurocognitive disorders (HAND) including the changing epidemiology, risk factors associated with its development, methods for screening for the disorders and evolving treatment options.

Entities:  

Mesh:

Year:  2011        PMID: 21745034     DOI: 10.1080/13548506.2011.579992

Source DB:  PubMed          Journal:  Psychol Health Med        ISSN: 1354-8506            Impact factor:   2.423


  14 in total

Review 1.  Microglial cell origin and phenotypes in health and disease.

Authors:  Kaoru Saijo; Christopher K Glass
Journal:  Nat Rev Immunol       Date:  2011-10-25       Impact factor: 53.106

2.  Translational spatial task and its relationship to HIV-associated neurocognitive disorders and apolipoprotein E in HIV-seropositive women.

Authors:  Diana Morales; Summer F Acevedo; Richard L Skolasky; Rosa Hechavarria; Sharon Santiago; Tania De La Torre; Elizabeth Maldonado; Valerie Wojna
Journal:  J Neurovirol       Date:  2012-09-13       Impact factor: 2.643

3.  Buprenorphine decreases the CCL2-mediated chemotactic response of monocytes.

Authors:  Loreto Carvallo; Lillie Lopez; Fa-Yun Che; Jihyeon Lim; Eliseo A Eugenin; Dionna W Williams; Edward Nieves; Tina M Calderon; Carlos Madrid-Aliste; Andras Fiser; Louis Weiss; Ruth Hogue Angeletti; Joan W Berman
Journal:  J Immunol       Date:  2015-02-25       Impact factor: 5.422

4.  Sexual discounting: A systematic review of discounting processes and sexual behavior.

Authors:  Matthew W Johnson; Justin C Strickland; Evan S Herrmann; Sean B Dolan; David J Cox; Meredith S Berry
Journal:  Exp Clin Psychopharmacol       Date:  2020-10-01       Impact factor: 3.157

5.  Applying the HIV-associated neurocognitive disorder diagnostic criteria to HIV-infected youth.

Authors:  Jacqueline Hoare; Nicole Phillips; John A Joska; Robert Paul; Kirsten A Donald; Dan J Stein; Kevin G F Thomas
Journal:  Neurology       Date:  2016-05-20       Impact factor: 9.910

6.  YWHAE/14-3-3ε: a potential novel genetic risk factor and CSF biomarker for HIV neurocognitive impairment.

Authors:  Diana Morales; Rosa Hechavarria; Valerie Wojna; Summer F Acevedo
Journal:  J Neurovirol       Date:  2013-08-27       Impact factor: 2.643

7.  Neurological Complications in Controlled HIV Infection.

Authors:  Kate M Crossley; Bruce J Brew
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

Review 8.  The role of human dopamine transporter in NeuroAIDS.

Authors:  Jun Zhu; Subramaniam Ananthan; Chang-Guo Zhan
Journal:  Pharmacol Ther       Date:  2017-10-05       Impact factor: 12.310

9.  Specific protein profile in cerebrospinal fluid from HIV-1-positive cART-treated patients affected by neurological disorders.

Authors:  Valentina Zanin; Serena Delbue; Annalisa Marcuzzi; Eleonora Tavazzi; Rossella Del Savio; Sergio Crovella; Enrico Marchioni; Pasquale Ferrante; Manola Comar
Journal:  J Neurovirol       Date:  2012-05-12       Impact factor: 2.643

10.  A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals.

Authors:  Thomas D Marcotte; Reena Deutsch; Benedict Daniel Michael; Donald Franklin; Debra Rosario Cookson; Ajay R Bharti; Igor Grant; Scott L Letendre
Journal:  J Neuroimmune Pharmacol       Date:  2013-10-08       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.